TScan Therapeutics Inc. Revenue 2020–2025
TScan Therapeutics Inc. annual/quarterly revenue history and growth rate from 2020 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- TScan Therapeutics Inc. revenue for the quarter ending March 31, 2026 was 982000, a 54.77% decrease year-over-year.
- TScan Therapeutics Inc. revenue for the twelve months ending March 31, 2026 was 8.7 M, a 44.75% increase year-over-year.
- TScan Therapeutics Inc. annual revenue for 2025 was 10.3 M, a 266.65% increase from 2024.
- TScan Therapeutics Inc. annual revenue for 2024 was 2.8 M, a 86.62% decrease from 2023.
- TScan Therapeutics Inc. annual revenue for 2023 was 21.0 M, a 55.52% increase from 2022.
- TScan Therapeutics Inc. annual revenue for 2022 was 13.5 M.
TScan Therapeutics Inc. (TCRX) — Frequently Asked Questions
TScan Therapeutics Inc. (TCRX) is a publicly traded US company. It has a market capitalization of $119M. In fiscal 2025 it reported revenue of $10M and net income of -$130M. Explore TCRX's stock price, financial statements, earnings history, margins and key ratios below.
What is TScan Therapeutics Inc.'s market cap?
TScan Therapeutics Inc. (TCRX) has a market capitalization of $119M.
What is the TCRX stock price?
TCRX trades at $0.92 (-4.92% on the day).
How much revenue does TScan Therapeutics Inc. make?
TScan Therapeutics Inc. reported revenue of $10M in fiscal 2025.
Is TCRX profitable?
In fiscal 2025, TScan Therapeutics Inc. reported net income of -$130M.